top of page

Search Results

Search results for "Can Cao"

Results found for "Can Cao"

  • Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization

    faster, and stay ahead in GPCR drug discovery with evidence-based insights—no hype, just strategies you can Breakthroughs this week: New work clarifies how active-state GPCR conformations can support coupling Available in four formats, it turns a notoriously tricky measurement into something discovery teams can pharmacology—showing how persistence, precision, and the courage to take on “impossible” chemistry can B y integrating them into GPCR workflows, discovery teams can accelerate identification, characterization

  • Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR

    achieve this, the work of Heydenreich et al. (2023) will be analysed to demonstrate how mutagenesis can By identifying key β2AR residues that influence efficacy and potency, pharmaceutical researchers can For example, orthosteric drug design —in which drugs bind to the receptor’s primary active site—can now Alternatively, allosteric modulators , which bind to sites outside the traditional ligand-binding pocket, can Understanding the evolutionary conservation of these residues can lead to the development of drugs that

  • Ben Clements on Rescuing Opioids with GPCR Modulators

    Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase His work highlights how foundational GPCR science can drive therapeutic innovation.

  • Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery

    “ A substitution of one amino acid by another in a protein can have effects ranging from negligible to While these structural techniques offer significant advantages in drug discovery, no single method can Furthermore, data on the role of specific residues within receptors can provide valuable insights for Through either random or targeted (site-directed) approaches, mutagenesis can provide a comprehensive In summary, mutagenesis can be a critical tool in drug discovery, particularly for studying GPCRs.

  • GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures

    For complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve Kenakin  showed how the same agonist can behave as near-full, partial, or even silent depending on receptor This is why experts never classify ligands from a single system: The same molecule can occupy different Kenakin  stressed that low-alpha NAMs can resemble competitive antagonists unless deeper kinetic or concentration-range Extremely strong binders can fail in structured tissues because they saturate the periphery and never

  • The Moment Biotech Founders Realize the Money Is Gone

    . 👉 How long can we operate if fundraising takes longer than expected? Which decisions can we still reverse, and which ones are already locked in? creates the illusion of control 👉 Many biotech founders  believe they are in control because they can They manage cash flow, but they do not actively track which strategic decisions can still be changed In reality, this is the last window where control can still be regained.

  • Chemokine receptor-targeted drug discovery: progress and challenges

    Redundancy can be exemplified by the tumor infiltration of Treg cells which can be driven directly by This redundancy can be seen as problematic in drug discovery as blocking a single receptor might not the chemokine-receptor system, different chemokines are able to activate different pathways, which can Signaling bias can be seen as complex as advantageous since selectively inhibiting certain signaling pathways while sparing others, can prevent some of the negative off-target effects.

  • Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game

    “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual iteratively refining the models with docking and mutagenesis data, they developed predictive pipelines that can

  • Asking Better Questions in Science: A Practical Guide for Emerging Researchers

    Yet one well-timed question can unlock clarity, accelerate a stalled project, or even spark a collaboration s a masterclass in asking better questions in science, not as a skill you’re born with, but one you can I’m running into a problem and I know you work on something similar — can I pick your brain for one minute

  • From Failed Experiments to Predictive GPCR Models

    He emphasizes that not every question can be answered computationally—and that saying “we don’t know” In a field where major publications and grant awards can be rare, finding satisfaction in an optimized Modeling a Career on Your Own Terms Carlsson’s career shows that failures can evolve into strengths and that computational insights can transform how we approach GPCRs. early-career researchers, the takeaway is direct: GPCR drug discovery will increasingly depend on those who can

  • A Note from Yamina: Building the Next Chapter of Dr. GPCR

    Learners can study at their own pace, shape the curriculum, and join live monthly AMA sessions with Dr Our access program for researchers in developing countries  continues as well: eligible scientists can 2026, our focus remains simple: keep building with purpose — strengthening what works, refining what can You can always reach me at hello@DrGPCR.org  — and yes, we read every email.

  • Understanding Enzyme Inhibition In GPCR Discovery Programs

    This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can Why CYP450 allostery can make or break translation from bench to bedside. Now — Premium Members Get Over 50% Discount at Checkout ➤ The Innovation Trap: Why Playing It Safe Can Why micro-domains change what “global” signaling can and can’t explain.

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    assays, signaling assays, cell imaging, protein structure determination, and omics applications, which can Classification: AI models can be used to distinguish GPCRs from non-GPCRs, and to classify GPCRs into Mutations: ML methods can determine stabilising mutations that enable structure determination and can Virtual screening: molecular docking and virtual screening can efficiently analyze large databases of Predicting GPCR properties: AI models can predict various properties of GPCRs, such as ligand binding

  • Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    BBVs are nanoparticles covered with Sf9 cell membranes different from mammalian membranes,[9] which can affect receptors’ properties.[10,11] BBVs also lack downstream signaling components, which can be an The speed of reaching the binding equilibrium is key for this assay, which can be monitored over time Altogether, these aspects hint that the linker design and strategy can provide options for the tuning CELT-419 binding to D3 receptors in cells can be clearly visualized with fluorescence imaging.

  • The Hidden Cost of Unclear Biotech Positioning

    Positioning 👉 Most biotech founders feel that something is wrong in external conversations long before they can stop adjusting their message mid-conversation , which increases confidence and coherence Alignment can Investors and partners can quickly assess relevance. Founders can quickly assess interest. External stakeholders can decide faster, and founders waste less energy trying to adapt. ✅ If every conversation

  • How Early Strategic Decision Making Creates Alignment and Better Results

    They give the comforting sense that progress can be measured and managed . Teams believe they can correct course by adjusting execution. How Founders Can Strengthen Strategic Decision Making Early Once founders recognize the role of early decisions and understand how alignment works, the next question becomes practical. 👉 How can strategic Founders who define when and how decisions can be challenged reduce fear and defensiveness later on.

  • Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology

    In GPCR drug discovery, a single mistaken assumption can derail an entire program. also explores the experimental constraints —like timing and equilibrium—that determine whether you can shape alone is diagnostic, pointing out how features like receptor reserve  or irreversible binding  can

  • Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery

    While these signaling pathways are highly interconnected, they can also be regulated independently (Kenakin In various pathological conditions, including cancer, aberrant ERK activity can lead to uncontrolled ERK activation pathways can be categorised into two main sub-pathways based on their subcellular localisation The choice of pathway can result in different cellular responses, underscoring the criticality of precise understanding the intricacies of GPCR signaling and utilising advanced assay technologies, researchers can

  • How Schild Analysis Protects Your Conclusions in GPCR Research

    Welcome back GPCR Fans, Clean data can still mislead if the underlying assumptions aren’t tested. But if the underlying criteria aren’t tested, that assumption can quietly erode the reliability of your Quantify affinity you can defend.  

  • Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today

    Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue Solubility, lipophilicity (e.g., logP), and polarity govern whether molecules can cross membranes, dissolve its path from administration to excretion Minor ADME adjustments —sometimes a single methyl group— can

  • The Boston Happy Hour: What Happens When GPCR Scientists Enter the Cafe

    GPCR exists to democratize this field, to create spaces where the most junior scientist in the room can You can relax. You belong here.

  • Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling

    While GPCRs can exist as monomers, some types, like class C GPCRs, are obligate dimers, either as homodimers class B GPCRs, however, has been more controversial, despite increasing evidence that these receptors can These dimeric forms, which can either be transient or stable, are believed to influence the function Recent studies suggest that class B1 GPCRs can form both homodimers and heterodimers, which may play

  • What If the Most Important Part of Your Drug Isn’t What It Binds—But What It Does?

    You'll learn why some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge can

  • Nanobodies: New Dimensions in GPCR Signaling Research

    They can recognize cryptic epitopes often composed of discontinuous amino acid segments and occur only Nbs can stabilize specific conformations of proteins, including unstable structural intermediates and Generation, selection and functional expression: Nanobodies can be obtained by immunizing a camelid and Combinatorial biology methods such as phage display, yeast display, and ribosome display can be used Most Nbs can be functionally expressed as genetically encoded intrabodies within a eukaryotic cell.

  • How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision

    Trusting your eyes—or tradition—can cost time, money, and credibility. walks you through which statistical tests actually answer the question you think you’re asking—so you can Get an answer you can defend. Unlock Terry’s Corner ➤ Dr.

  • Fluorescence Polarization in GPCR Research

    Using this method, binding affinity, kinetics and selectivity can all be measured and used to establish This combined with the use of polarized light leads to a signal that can only be detected when the fluorescent Conventional membrane preparations or baculoviruses can be used among others.

  • When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue

    I can image the whole islet. A single successful GPCR imaging experiment can transform a project’s trajectory. Better GPCR imaging doesn’t just capture biology — it expands the biological questions the field can

  • A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery

    other immune checkpoint inhibitors.1 In a shared effort to develop robust screening approaches  that can They can be used to verify target engagement  and calculate ligand affinity  in a NanoBRET ®-based competitive As a proof of concept, the study shows that Celtarys’ chemistry can be translated into NanoBRET ® TE The next step will be to determine how broadly this approach can be extended across GPCR families and

  • GPCR Selectivity Beyond the Receptor

    Key implications: SBI-553 illustrates how arrestin signaling can be stabilized through direct receptor–Gαo interface engagement rather than distal conformational effects PCO371 shows that G protein bias can arginine residue, distinct from agonist recognition Explore the masterclass library ➞ Premium Members can

  • The Real Cost of Strategic Overload in Biotech

    Each move can be justified. Early data can point in multiple promising directions. Letting go of a program can feel like abandoning potential value. Can the entire strategy be explained through one coherent throughline, or does it require layered justifications

bottom of page